Paper286122
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
Fuji H and 2 others. J Natl Cancer Inst, 1979. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods. Papers, record 286122. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/286122
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Neoplasm | Major topic |
| Antigens, Neoplasm | Major topic |
| Leukemia L1210 | Major topic |
| Lymphoma | Major topic |
| Animals | |
| Cell Membrane | |
| Cross Reactions | |
| Cytotoxicity, Immunologic | |
| Female | |
| H-2 Antigens | |
| In Vitro Techniques | |
| Isoantibodies | |
| Mice | |
| Mice, Inbred DBA | |
| Transplantation Immunology |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 6,559,105 | Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6559105 | PubMed |
| 6,553,510 | Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6553510 | PubMed |
| 6,435,857 | Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6435857 | PubMed |
| 6,192,904 | Intratumor immunologic heterogeneity. | Cancer Metastasis Rev | 1982 | https://conductscience.org/library/papers/6192904 | PubMed |
| 3,933,817 | Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. | Cancer Immunol Immunother | 1985 | https://conductscience.org/library/papers/3933817 | PubMed |
| 3,632,916 | Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/3632916 | PubMed |
| 2,458,749 | DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity. | Br J Cancer | 1988 | https://conductscience.org/library/papers/2458749 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/286122
GET https://conductscience.org/api/papers/v1/286122/authors